{"id":"administration-of-vorolanib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":{"chemblId":"CHEMBL4297587","moleculeType":"Small molecule","molecularWeight":"439.49"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Vorolanib works by blocking VEGFR signaling pathways, which are critical for new blood vessel formation that tumors depend on for growth and metastasis. By inhibiting these receptors, the drug starves tumors of their blood supply while also potentially having direct anti-proliferative effects on cancer cells. This mechanism is typical of anti-angiogenic small molecule kinase inhibitors used in oncology.","oneSentence":"Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) to inhibit angiogenesis and tumor growth.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:19:47.478Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 2 investigation)"}]},"trialDetails":[{"nctId":"NCT07386158","phase":"PHASE2","title":"Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-10","conditions":"Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy","enrollment":21},{"nctId":"NCT06676527","phase":"","title":"Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2024-09-01","conditions":"Neoplasms, Kidney Neoplasms, Urologic Neoplasms","enrollment":39},{"nctId":"NCT07165418","phase":"PHASE3","title":"A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-25","conditions":"Renal Cell Carcinoma (RCC)","enrollment":116},{"nctId":"NCT07047001","phase":"PHASE2","title":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dong Wen","startDate":"2025-04-24","conditions":"Renal Cell Carcinoma (RCC), Adjuvant","enrollment":60},{"nctId":"NCT06728852","phase":"PHASE2","title":"Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","status":"RECRUITING","sponsor":"Li-kun Chen","startDate":"2024-12-01","conditions":"Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy","enrollment":32},{"nctId":"NCT03583086","phase":"PHASE1, PHASE2","title":"Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2018-07-10","conditions":"Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors","enrollment":88},{"nctId":"NCT06585878","phase":"NA","title":"A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-09-01","conditions":"Renal Cell Carcinoma, RCC, Kidney Cancer","enrollment":60},{"nctId":"NCT06577961","phase":"PHASE1, PHASE2","title":"Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-31","conditions":"Kidney Cancer, RCC, Renal Cell Carcinoma","enrollment":37},{"nctId":"NCT06523049","phase":"PHASE2","title":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","status":"NOT_YET_RECRUITING","sponsor":"Hao Zeng","startDate":"2024-08","conditions":"Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy","enrollment":67},{"nctId":"NCT06406673","phase":"PHASE2","title":"A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-10-16","conditions":"Extensive Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT03792958","phase":"PHASE1","title":"Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2019-02-26","conditions":"Advanced Malignant Solid Tumors","enrollment":19},{"nctId":"NCT04222842","phase":"PHASE1","title":"CM082 in Patients With Myopic Choroidal Neovascularization (CNV)","status":"SUSPENDED","sponsor":"AnewPharma","startDate":"2019-12-18","conditions":"Myopic Choroidal Neovascularisation","enrollment":96},{"nctId":"NCT03511222","phase":"PHASE1","title":"Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-09-11","conditions":"Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer","enrollment":16},{"nctId":"NCT03848611","phase":"PHASE2","title":"CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2019-04-02","conditions":"Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03904719","phase":"PHASE2","title":"CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2019-09-18","conditions":"Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04126668","phase":"PHASE1","title":"A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"AnewPharma","startDate":"2019-12-19","conditions":"Advanced Malignant Solid Tumors","enrollment":24},{"nctId":"NCT03710863","phase":"PHASE2","title":"Safety and Tolerability of Oral CM082 in Patients With wAMD","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2018-11-22","conditions":"Age-Related Macular Degeneration","enrollment":64},{"nctId":"NCT03602547","phase":"PHASE2","title":"Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2018-07-31","conditions":"Mucosal Melanoma","enrollment":40},{"nctId":"NCT03286244","phase":"PHASE1","title":"Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2018-03-15","conditions":"Advanced Gastric Cancer","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Administration of Vorolanib","genericName":"Administration of Vorolanib","companyName":"Li-kun Chen","companyId":"li-kun-chen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vorolanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) to inhibit angiogenesis and tumor growth. Used for Advanced or metastatic solid tumors (Phase 2 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}